Zheng Jian, Wei Yuntao, Li Xiaoxi, Shen Zhan, Zhang Yong, Huang Bo, Jiang Youhong, Wang Daqing
Molecular Oncology Laboratory of Cancer Research Institute, The First Hospital of China Medical University, Shenyang, China.
Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Breast Care (Basel). 2022 Feb;17(1):31-39. doi: 10.1159/000513502. Epub 2021 Mar 15.
The aim of this study was to measure the expression of PD-L1, CD1a (a marker for immature dendritic cells), and CD83 (a marker for mature dendritic cells) and further examine the associations of PD-L1, CD83, and CD1a with overall survival (OS) in triple-negative breast carcinoma patients.
PD-L1, CD1a, and CD83 expression in breast carcinoma tissues and CD83 expression in lymph node tissues were examined by immunohistochemistry and tissue microarray in 159 patients. Patients were classified into the low, medium, and high PD-L1, CD1a, and CD83 levels. Pearson χ test was used to analyze the correlations between PD-L1, CD1a, and CD83. The Kaplan-Meier method was used to calculate the OS. Multivariate analysis was used to identify determinants of 3- and 5-year OS.
25.1, 25.8, and 49.1% of the patients had low, medium, and high PD-L1 levels, respectively. PD-L1 levels significantly correlated with CD1a ( = 0.30409, < 0.001) and CD83 levels ( = 0.6146, < 0.001) in breast carcinoma tissue, as well as CD83 levels ( = 0.17508, = 0.027) in lymph node. The median OS was 83 months (range 12-106), and the 3- and 5-year OS rates were 94.97% (95% CI 91.57-98.37) and 86.79% (95% CI 81.53-92.06), respectively. Moreover, patients with high median CD1a levels had a significantly lower 5-year OS rate (75.6%) than those with low median CD1a levels (93.5%, = 0.038).
PD-L1, CD1a, and CD83 are variably expressed in triple-negative breast carcinoma tissues, and PD-L1 expression correlates with CD1a and CD83. Higher CD1a levels correlate with PD-L1 expression and predict worse OS in triple-negative breast carcinoma.
本研究旨在检测程序性死亡受体配体1（PD-L1）、CD1a（未成熟树突状细胞标志物）和CD83（成熟树突状细胞标志物）的表达，并进一步探讨PD-L1、CD83和CD1a与三阴性乳腺癌患者总生存期（OS）的相关性。
采用免疫组织化学和组织芯片技术检测159例患者乳腺癌组织中PD-L1、CD1a和CD83的表达以及淋巴结组织中CD83的表达。将患者分为PD-L1、CD1a和CD83低、中、高表达组。采用Pearson χ检验分析PD-L1、CD1a和CD83之间的相关性。采用Kaplan-Meier法计算总生存期。多因素分析用于确定3年和5年总生存期的决定因素。
分别有25.1%、25.8%和49.1%的患者PD-L1表达为低、中、高。在乳腺癌组织中，PD-L1水平与CD1a水平（r = 0.30409，P < 0.001）和CD83水平（r = 0.6146，P < 0.001）显著相关，在淋巴结中，PD-L1水平与CD83水平（r = 0.17508，P = 0.027）显著相关。总生存期的中位数为83个月（范围12 - 106个月），3年和5年总生存率分别为94.97%（95%CI 91.57 - 98.37）和86.79%（95%CI 81.53 - 92.06）。此外，CD1a中位数水平高的患者5年总生存率（75.6%）显著低于CD1a中位数水平低的患者（93.5%，P = 0.038）。
PD-L1、CD1a和CD83在三阴性乳腺癌组织中表达各异，PD-L1表达与CD1a和CD83相关。较高的CD1a水平与PD-L1表达相关，并预示三阴性乳腺癌患者总生存期较差。
